At the start of most conversations we have at Single Point of Contact, leadership teams ask about prevention, firewalls, endpoint security, compliance checklists.
But the real question isn’t how you prevent an attack.
It’s this:
If an attacker is already inside your environment…how long would it take you to know?
Because in biotech, the damage doesn’t begin at entry.
It begins during the silence.
The Reality: Attackers Don’t Rush
In industries like biotech, attackers behave differently.
They don’t smash and grab.
They wait, observe, and extract value slowly, because your environment stores valuable assets, such as:
- Proprietary research data
- Clinical trial results
- Intellectual property tied to valuation
- Regulated patient and partner data
And here’s the uncomfortable truth:
The longer an attacker stays undetected, the more strategic the damage becomes.
Real-World Reminder
When Enzo Biochem was breached, sensitive patient data tied to millions of individuals was exposed.
When Inotiv was hit, operations were disrupted and data compromised.
These weren’t instant events.
They were failures in detection timing.
The Question Most Leaders Can’t Answer
Ask your internal team one question:
“What is our current attacker dwell time?”
Most organizations cannot answer this.
Not because they lack tools.
But because they lack visibility across systems, endpoints, identities, and behavior patterns.
And if you don’t know your dwell time…
You don’t know your exposure window.
What Happens During Undetected Dwell Time
While leadership assumes systems are “secure,” attackers are often:
- Mapping your network and identifying critical systems
- Escalating privileges quietly across environments
- Monitoring internal communications and workflows
- Exfiltrating small amounts of data over time
- Positioning ransomware or destructive payloads
This isn’t noise. This is strategy unfolding inside your environment.
Why Traditional Security Fails Here
Most biotech firms rely on:
- Endpoint tools generating alerts
- SIEM platforms collecting logs
- Periodic audits or compliance reviews
But here’s the gap:
Alerts don’t equal detection.
Without:
- 24×7 monitoring
- Behavioral analysis
- Human-led investigation
- Defined response timelines
…those alerts become background noise.
The Leadership Blind Spot
This is where the issue becomes strategic, not technical.
Because the real risk isn’t:
“Do we have security tools?”
It’s:
“Do we know when those tools fail to detect real threats?”
Executives often assume:
- Compliance = security
- Tools = protection
- IT teams = full visibility
But attackers don’t operate within compliance frameworks.
They operate within your blind spots.
The Cost of Not Knowing
If an attacker remains inside your network for weeks or months, the consequences escalate:
- Intellectual property theft before patents are secured
- Clinical trial disruption affecting timelines and funding
- Regulatory exposure across HIPAA, FDA, GDPR
- Loss of investor confidence due to delayed breach disclosure
- Operational downtime at critical research stages
At that point, the question shifts from IT to leadership:
“Why didn’t we know sooner?”
What Strong Detection Actually Looks Like
Organizations that reduce dwell time don’t rely on tools alone.
They implement:
- 24×7 monitoring across endpoints, networks, and cloud systems
- Correlation of signals across multiple data sources
- Threat intelligence to identify emerging attack patterns
- Defined response SLAs
- Continuous validation of detection capabilities
Because detection isn’t a product.
It’s a capability.
The Strategic Shift
Biotech leadership needs to reframe the conversation:
From:
- “Are we protected?”
To:
- “How fast can we detect and respond to an active threat?”
That shift alone separates organizations that recover…
From those that explain losses to investors.
Final Thought
If you cannot clearly answer:
- How long an attacker could remain undetected
- Who is actively monitoring your environment at 2am
- How quickly a real threat is investigated and contained
Then you don’t have a detection strategy. You have assumptions.
At Single Point of Contact, we work with biotech firms to reduce detection gaps, validate visibility, and ensure threats don’t remain invisible long enough to cause irreversible damage.
If this question made you uncomfortable…It should. Now is the time to address it.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
